In a pioneering advance that reshapes our understanding of immune regulation, researchers have unveiled the molecular underpinnings of C5aR2, a complement receptor that defies classical signaling norms. This receptor, known to operate in tandem with C5aR1 to mediate the potent inflammatory effects of the complement anaphylatoxin C5a, has remained a conundrum due to its atypical signaling properties and elusive ligand recognition mechanisms. The latest study, employing cutting-edge cryo-electron microscopy (cryo-EM), sheds light on the structural configurations through which C5aR2 orchestrates biased signaling favoring β-arrestins over G proteins—a revelation that charts new territory in immunopharmacology.
C5a, an essential component of the complement cascade, is recognized for its ability to provoke rapid and robust inflammatory responses via engagement with G protein-coupled receptor C5aR1. Conventional wisdom posited that its partner receptor, C5aR2, played a secondary or modulatory role, largely because C5aR2 deviates from canonical G protein coupling. Instead, it preferentially recruits β-arrestins, signaling molecules involved in receptor desensitization and alternative intracellular pathways. Delving deeply into this phenomenon has been challenging, but the advent of cryo-EM technology has allowed unprecedented visualization of these complex receptor-transducer assemblies.
The research team succeeded in capturing the intricate cryo-EM structures of both C5aR2 and C5aR1 bound to β-arrestin 1, triggered by stimulation from native C5a and its truncated metabolite, C5adesArg. These snapshots expose a suite of critical structural features within C5aR2 that preclude traditional G protein coupling. Notably, subtle but crucial conformational differences in the transmembrane domains and intracellular loops dictate an intrinsic bias toward arrestin engagement. This discovery not only elucidates the physical basis for the receptor’s atypical signaling but also clarifies how C5aR2 fine-tunes immune responses distinct from those mediated by C5aR1.
One of the study’s landmark contributions lies in its comparative structural interrogation between C5aR2 and C5aR1. While both receptors bind the identical ligand C5a, their methods of ligand engagement differ markedly. For instance, C5aR2 exhibits a unique ligand-recognition mechanism that accounts for its maintained high affinity for C5adesArg, a metabolite with significantly reduced activity toward C5aR1. The structural data reveal specialized interactions within the extracellular domains of C5aR2 that stabilize this metabolite binding, explaining prior biochemical observations that had puzzled immunologists for years.
Building on these mechanistic insights, the team embarked on a rational drug design campaign that culminated in the synthesis of ZQ105, a highly selective agonist that targets C5aR2 with exceptional specificity. Unlike broader complement modulators, ZQ105 exploits the unique structural determinants of C5aR2, serving as a precision tool to dissect its function without off-target activation of C5aR1 pathways. The ability to selectively engage C5aR2 opens new avenues for manipulating inflammatory processes with a level of control previously unattainable in complement-targeted therapies.
Employing ZQ105 as a chemical probe, functional assays in neutrophils—central players in innate immunity—uncovered that selective C5aR2 activation triggers discrete pro-inflammatory pathways distinct from those initiated by C5aR1. Additionally, this selective activation promotes receptor internalization, implicating C5aR2 in regulating neutrophil trafficking and function in inflammation. These responses underscore the receptor’s role not merely as a decoy or scavenger but as an active participant in shaping immune dynamics.
This study’s impact extends beyond the complement system itself, contributing fundamentally to our understanding of biased signaling in G protein-coupled receptors (GPCRs), which are among the most pharmacologically relevant targets in medicine. The clear visualization of β-arrestin coupling to C5aR2 contrasts with traditional GPCR paradigms and illustrates how structural features can direct signaling biases that tailor cellular outcomes. These insights may inform drug discovery targeting other atypical receptors with therapeutic potential in autoimmunity, infectious diseases, and beyond.
Furthermore, the refined comprehension of C5aR2’s ligand selectivity has implications for complement-mediated pathologies such as sepsis, systemic lupus erythematosus, and other inflammatory disorders. By distinguishing ligand affinities and signaling outcomes with atomic precision, researchers can better predict receptor behavior under physiological and pathological conditions. The selective modulation of C5aR2 activity might represent a breakthrough in dampening excessive inflammation without compromising host defense.
The cryo-EM structures also prime the field for future explorations into receptor dynamics, ligand bias, and the crosstalk between complement components and the broader immunological network. The interplay between C5aR1 and C5aR2—once considered a simple agonist-receptor pair—emerges as a sophisticated system modulating immune cell function via distinct intracellular signals. This complexity underscores the need for more nuanced therapeutic strategies that can exploit receptor-specific pathways to achieve immunomodulation.
Intriguingly, the revelation of arrestin-biased signaling mechanisms in C5aR2 challenges conventional receptor pharmacology and aligns with growing evidence that receptor function cannot merely be classified as ‘on’ or ‘off’ through G protein interaction. Instead, it attests to the exquisite versatility of cellular receptors to adopt multiple signaling modes according to structural configuration and ligand context, expanding the therapeutic landscape with ‘biased agonists’ like ZQ105 that harness these variations for benefit.
Considering the diverse roles of neutrophils in host defense and inflammatory disease pathogenesis, the implications of C5aR2’s selective activation on neutrophil behavior are profound. By modulating functions ranging from cytokine release to chemotaxis and receptor trafficking, C5aR2 emerges as a potential target for controlling neutrophil-driven tissue damage, chronic inflammation, and immune dysregulation. The availability of selective ligands could thus revolutionize approaches to conditions where neutrophil hyperactivity is detrimental.
Finally, this research represents a milestone in structural immunology—a field increasingly reliant on high-resolution technologies to decipher receptor complexes that were previously inaccessible. The detailed molecular blueprints provided here pave the way for rational drug development not only targeting complement receptors but also inspiring innovations in targeting other arrestin-coupled GPCRs that modulate critical physiological and pathological processes.
As the study’s insights permeate through biomedical research, the fusion of structural biology, immunology, and pharmacology embodied by this work exemplifies the future of precision medicine. By illuminating the atypical yet crucial role of C5aR2 in complement signaling, scientists now stand better equipped to design innovative therapies that harness the immune system’s complexity to combat disease while minimizing collateral damage.
Subject of Research: Complement receptor C5aR2, β-arrestin biased signaling, ligand recognition, and selective agonist discovery.
Article Title: Atypical signaling, ligand recognition and selective agonist discovery of complement receptor C5aR2
Article References:
Qin, J., Cai, C., Shan, M. et al. Atypical signaling, ligand recognition and selective agonist discovery of complement receptor C5aR2. Cell Res (2026). https://doi.org/10.1038/s41422-026-01273-1
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41422-026-01273-1
